from the desk of f_the_bankers (for your eyes only)so, we hear a lot about Concordia and how cheap it is based on its earnings, etc. but, these earnings are non-gaap. a big component of these non-gaap earnings is amortization of their debt. by the time Concordia's debt is paid off, will their drug portfolio still be as lucrative as it is now? most of their drugs are either patented or not, orphan, or generic. orphan drugs are by definition underdeveloped and of little profitability commercially. as a company, like Concordia, raises its drug prices many 100 of % other pharmaceutical companies will develop competing drugs. these are some of the concerns I have with Concordia. in addition you have the shorting boogeyman, the stock price trend from a technical standpoint, companies like cvs dropping their products, brexit (=currency and recession risk), valeant guilt by association, and the u.s. presidential healthcare platforms. the good news is... I can't imagine what else bad can go wrong for the company. so, maybe, i'll give it a week and dip my toe in.